The abstract is read at the publisher; the summary is JClub's.
Genome-wide cfDNA methylation in 491 pre-diagnosis breast and prostate plasma samples predicts future prostate cancer risk up to eight years, with high-risk individuals showing a 3.55-fold increased hazard.
- Why it matters: Early detection is limited because clinical signals appear late; identifying cancer-associated epigenetic changes in blood before diagnosis could enable earlier risk stratification and surveillance.
- What they did: The study profiled cfDNA methylation genome-wide in pre-diagnosis plasma, some collected up to nine years before diagnosis, then trained logistic regression models on a discovery set to test predictive methylation signatures.
- The result: cfDNA silencer-region methylation robustly predicted incident prostate cancer, while enhancer hypermethylation modestly predicted incident breast cancer and strongly distinguished established late-stage breast cancers, with a 2.3-fold increased hazard.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.